Posted by Michael Wonder on 04 Aug 2022
Travere Therapeutics provides regulatory updates on its development programs
3 August 2022 - Pegtibatinase granted breakthrough therapy designation by FDA.
The FDA recently granted breakthrough therapy designation to pegtibatinase, the company’s novel investigational enzyme replacement therapy being evaluated for the treatment of homocystinuria.
